These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37470155)

  • 1. Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia.
    Aldoss I; Tizro P; Bedi D; Mangan JK; Clark MC; Spencer D; Song JY; Cherian S; Pillai R; Kim Y; Mahajan N; Gendzekhadze K; James M; Jacobs K; Davidson-Moncada J; Forman SJ; Wang HY; Afkhami M
    Haematologica; 2023 Dec; 108(12):3511-3516. PubMed ID: 37470155
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
    Zhang X; Yang J; Li J; Qiu L; Zhang J; Lu Y; Zhao YL; Jin D; Li J; Lu P
    Am J Hematol; 2023 Dec; 98(12):1898-1908. PubMed ID: 37740926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. InsT-ALLing CD7 chimeric antigen receptors before transplantation.
    Delgado J
    Br J Haematol; 2024 Jun; 204(6):2155-2156. PubMed ID: 38676290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
    Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X
    J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
    Mikhailova E; Illarionova O; Shelikhova L; Zerkalenkova E; Molostova O; Olshanskaya Y; Novichkova G; Maschan A; Maschan M; Popov A
    Haematologica; 2022 Apr; 107(4):970-974. PubMed ID: 34911282
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.
    Suematsu M; Yagyu S; Yoshida H; Osone S; Nakazawa Y; Sugita K; Imamura T; Iehara T
    Cancer Immunol Immunother; 2023 Apr; 72(4):957-968. PubMed ID: 36214866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.
    Maciocia PM; Wawrzyniecka PA; Maciocia NC; Burley A; Karpanasamy T; Devereaux S; Hoekx M; O'Connor D; Leon T; Rapoz-D'Silva T; Pocock R; Rahman S; Gritti G; Yánez DC; Ross S; Crompton T; Williams O; Lee L; Pule MA; Mansour MR
    Blood; 2022 Jul; 140(1):25-37. PubMed ID: 35507686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
    Lu P; Liu Y; Yang J; Zhang X; Yang X; Wang H; Wang L; Wang Q; Jin D; Li J; Huang X
    Blood; 2022 Jul; 140(4):321-334. PubMed ID: 35500125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chimeric antigen receptor (CAR) T cells targeting CD19 for acute lymphoblastic leukemia].
    Takahashi Y; Nishio N
    Rinsho Ketsueki; 2023; 64(9):1184-1191. PubMed ID: 37899199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells.
    El Marabti E; Abdel-Wahab O
    Clin Cancer Res; 2023 Feb; 29(4):694-696. PubMed ID: 36507801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy.
    Chen W; Shi H; Liu Z; Yang F; Liu J; Zhang L; Wu Y; Xia Y; Ou Y; Li R; Zhang T; Zhang J; Ke X; Hu K; Yu J
    Clin Cancer Res; 2023 Apr; 29(8):1484-1495. PubMed ID: 36735547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
    Ni F; Yin ETS; Zhou L; Zhao H; Luo Y; Shi J; Hu Y; Huang H
    Bone Marrow Transplant; 2022 Feb; 57(2):326-328. PubMed ID: 35067672
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-CD19 chimeric antigen receptor T-cell therapy for B-cell acute lymphoid leukemia.
    Rapoport AP
    Haematologica; 2024 Apr; 109(4):1019-1020. PubMed ID: 38562075
    [No Abstract]   [Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
    Gauthier J; Turtle CJ
    Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
    Jiang Y; Feng D; Zhu J; Wei D; Zhao C; Liu H; Shao S; Wang C
    Front Immunol; 2024; 15():1381308. PubMed ID: 38745670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
    Myers RM; Dolan J; Teachey DT
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation.
    Xu Q; Xu H; Xue L; Wang M; Pan G; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Xu H; Liu X; Zhu X; Sun Z; Yang L; Wang X
    Chin Med J (Engl); 2022 Jan; 135(1):98-100. PubMed ID: 33967196
    [No Abstract]   [Full Text] [Related]  

  • 19. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
    Bayón-Calderón F; Toribio ML; González-García S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months.
    Yao Z; Gu B; Chen J; Xu Y; Chen F; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Zhang Y; Wu D; Wang Y
    Blood Cancer J; 2023 May; 13(1):75. PubMed ID: 37164955
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.